AnnJi Pharmaceutical News
Dedicated to New Drug Development in Dermatology & Neurology
AnnJi Pharmaceutical was Acknowledged by Kennedy’s Disease Associations in the US and UK as a Proud Sponsor of Their International Fundraising event,“The Great Road Trip”
To raise awareness of Kennedy’s Disease and to bring resources to support relevant research programs, AnnJi supported the international fundraising activities co-organized by the Kennedy’s Disease Association in the UK and the US, “The Great Road Trip” in early 2022.
In the “Great Road Trip”, the donors and volunteers took turns driving a 40-year-old Citroen 2CV. Citroen 2CV departed from Los Angeles, USA in April 2022 and arrived in Rome, Italy in July. Kennedy’s Disease Associations extended their appreciation of AnnJi Pharmaceutical’s contribution to the event and shared a video about the successful “The Great Road Trip” event.
Kennedy’s disease is a rare, inherited, neuro-muscular disease that primarily affects men. The illness causes muscle weakness and wasting throughout the body, often leading to difficulties with speech, swallowing, and mobility, as it progresses. Currently, there is no effective treatment for Kennedy’s disease.
AnnJi plans to initiate the enrollment of a first-in-patient Phase II clinical study of AJ201 for the treatment of Kennedy’s disease by the end of 2022. AJ201 is a first-in-class new drug developed by AnnJi and has been granted orphan drug designations (ODDs) by the USFDA for Kennedy’s disease, Huntington’s disease, and Spinocerebellar ataxia. Joining forces with Kennedy’s Disease Associations, AnnJi looks forward to bringing a safe and effective treatment to Kennedy’s disease patients by working together.